Transthera Sciences (Nanjing) Inc. has announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.
NLRP3 inflammasome inhibitors have been disclosed in a Kodiak Sciences Inc. patent and described as useful for the treatment of atherosclerosis, gout, rheumatoid arthritis, inflammatory bowel, Alzheimer’s, Parkinson diseases, multiple sclerosis and glaucoma.
China Pharmaceutical University has synthesized kaurane tetracyclic diterpenoid derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of arthritis and skin disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s and Alzheimer’s diseases.
Ventus Therapeutics US Inc. has disclosed oxoindolinyl amide derivatives acting as NLRP3 inflammasome inhibitors. As such, they are reported to be useful for the treatment of cancer, metabolic, autoimmune diseases, liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Aberrant NLRP3 inflammasome activation is at the root of a wide number of conditions, from heart, gastrointestinal, kidney or liver disorders to neuroinflammatory diseases such as Parkinson’s disease or multiple sclerosis. Researchers from Nodthera Ltd. have reported on NT-0796, an NLRP3 inflammasome inhibitor with an in vivo brain penetration profile.
Genfit SA has highlighted its new focus and development strategy in acute-on-chronic liver failure (ACLF). The company's pipeline targets key pathophysiological pathways of ACLF, with priority given to systemic inflammation, cell death and microbiota.
